Yet this simple difference translated into a median progression-free survival (PFS) of 11.3 months versus 5.7 months for ...

Novo Nordisk’s Alhemo (concizumab-mtci) has been approved by the US Food and Drug Administration (FDA) to prevent or reduce ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The new initiative, FDA PreCheck, was developed in response to President Donald Trump’s executive order to accelerate the ...

The most widely used measure of health-related self-efficacy is the Patient Activation Measure (PAM). It is a ...

This Phase III global clinical trial for patients with either stage IIIB or IV unresectable melanoma involved 118 research ...

The Medscape Global team is bringing their leading cardiology education and proven impact to the European Society of ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

In response, medical communications planning has become increasingly integrated, allowing customised user experiences across ...

Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new president and chief executive officer (CEO).